


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
SINO BIOPHARMACEUTICAL AWARDED
“2023 FORBES CHINA ESG INNOVATIVE ENTERPRISE”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharmaceutical**”, together with its subsidiaries, the “**Group**”) announces that, Sino Biopharmaceutical has been recognized by Forbes China as a “2023 Forbes China ESG Innovative Enterprise” for its excellence in implementation of environmental, social and governance (“**ESG**”) innovative practices.

Launched by Forbes China, the “2023 Forbes China ESG Innovative Enterprise Selection” aims to showcase the differentiated strengths of pioneering companies in the area of ESG innovation and their outstanding contributions to regional and global challenges, and to help the entire business community move towards a more sustainable future.

The selection was based on four criteria, namely “corporate growth, ESG practice, innovation execution and industry influence”, covering a wide range of industries such as pharmaceutical, finance, energy, environmental protection, industrial manufacturing, real estate and enterprise technology, in order to recognize the representative ESG innovation samples among Chinese enterprises, showcase the ESG innovation achievements of Chinese enterprises, and analyse and discover the status quo and the future trend of ESG development in China. After months of evaluation by the judging panel comprised of experts, Sino Biopharmaceutical stood out from the rest with its forward-looking innovative practices in the ESG field.

As a leading innovative research and R&D-driven pharmaceutical group in China, Sino Biopharmaceutical has always insisted on technological innovation, and continued to accelerate differentiated and internationalized innovation, contributing more strength in the promotion of the high-quality development of the pharmaceutical industry in China and establishment of a community of healthcare for human beings. The Group's investment in R&D in 2022 amounted to RMB4.454 billion, representing a year-on-year growth of 16.6%. No matter in terms of absolute value, growth rate or percentage of investment, the investment of Sino Biopharmaceutical in innovation and R&D is among the top of the industry. At present, the Company's innovation transformation is entering the harvesting period, with net revenue from innovative drugs reaching RMB6.75 billion in 2022, representing a year-on-year growth of 20%.

While insisting on R&D innovation, Sino Biopharmaceutical adheres to the concept of sustainability and is committed to fulfilling the Group's corporate mission of "improving the quality of life and safeguarding human dignity" through quality ESG management. We have introduced a number of ESG innovative initiatives in the areas of corporate governance, environmental protection and social responsibility, and has achieved good results.

In terms of corporate governance, the Group has continued to enhance professionalism, independence and diversity of the Board, and ensured that ESG is fully considered in all major decision-making processes. At the same time, the Group is committed to conducting its business activities in accordance with the highest ethical standards, building a business ecosystem of integrity, honesty and ethics, and striving to create an open and transparent corporate culture.

In terms of environmental protection, Sino Biopharmaceutical has always practised the concept of green development and continued to establish environmentally friendly enterprises, with a number of key member enterprises being honored with the title of "Green Factory" at the provincial and national levels. Meanwhile, the Group has formally launched the "Carbon Neutral Pathway Planning Project" to systematically promote low-carbon transformation measures such as manufacturing process optimization, iteration of energy-consuming equipment, use of renewable energy and construction of green industrial chains, so as to practically reduce greenhouse gas emissions.

In terms of social responsibility, Sino Biopharmaceutical actively innovates and develops a variety of public welfare and charitable activities to contribute to philanthropic causes. Since 2020, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a member of the Group, has co-launched a public welfare project called "Clear Sky Project" to raise funds for families of patients suffering from serious illnesses in need and to help them to overcome difficulties. As of October 2023, the total funds raised from the program exceeded RMB26 million, with more than 1.47 million participants.

In the future, Sino Biopharmaceutical will insist on innovation-driven development, and join hands with employees and partners from all walks of life to create a sustainable future. By leveraging the unity of knowledge and action, we will strive for the health and well-being of more patients, create a win-win situation for the environment and the society, and help the society move forward to a more sustainable future.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 4 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.